
CG Oncology Stock Jumps 14% on Positive Phase 3 Bladder Cancer Trial Data
The company said its PIVOT-006 trial cut recurrence risk by 68% and updated the timing and scope of its BCG-unresponsive filing, now expected in March 2027.
CG Oncology, Inc. · Nasdaq · Biological Products, (No Diagnostic Substances)

The company said its PIVOT-006 trial cut recurrence risk by 68% and updated the timing and scope of its BCG-unresponsive filing, now expected in March 2027.
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Nov. 18, 2026 | Arthur Kuan Chief Executive Officer, director | Bought | 30,000 | $78.88 | $2.37 million |
| Nov. 18, 2026 | Isabel Kalofonos Chief Commercial Officer · indirect | Bought | 3,751 | $79.76 | $299,161 |
| Nov. 16, 2026 | Leonard E. Post director | Sold 10b5-1 plan | 1,000 | $92.00 | $92,000 |
| Oct. 15, 2026 | Leonard E. Post director | Sold 10b5-1 plan | 1,000 | $62.07 $61.65-$62.48 | $62,065 |
| Sept. 15, 2026 | Leonard E. Post director | Sold 10b5-1 plan | 1,000 | $72.98 | $72,980 |
| Aug. 14, 2026 | Leonard E. Post director | Sold 10b5-1 plan | 1,000 | $74.54 | $74,540 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Regulation FD disclosure · Other events · Financial statements and exhibits
AI summary, unreviewedCG Oncology Reports Positive Phase 3 PIVOT-006 Topline Data: 68% Reduction in Recurrence Risk (HR 0.32) in Intermediate-Risk and HG Ta NMIBC; BCG-Unresponsive BLA Timing Pushed to March 2027
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedCG Oncology Q3 2026 EPS of -$0.64 Beats -$0.81 Consensus; Revenue $1.6 Million Tops $0.5 Million Estimate